Recombinant Human CCL19 Protein

• Cat.No.: CCL19-12H
• Product Overview: Recombinant Human CCL19 Protein without tag was expressed in E. coli.

Specification

• Description: Macrophage inflammatory protein-3 beta (MIP-3 β), also called CCL19, is a chemokine that is expressed in the thymus, lymph nodes, and activated bone marrow stromal cells. MIP-3 β signals through the G protein-coupled receptor CCR7 to regulate normal lymphocyte recirculation. MIP-3 β also functions during T cell trafficking to the thymus, and in T cell and B cell homing to the lymph nodes and secondary lymphoid organs. Human MIP-3 β shows activity on mouse cells.
• Source: E. coli
• Species: Human
• Bio-activity: No biological activity data is available at this time.
• Molecular Mass: Monomer, 8.8 kDa (77 aa)
• AA Sequence: GTNDAEDCCLSVTQKPIPGYIVRNF HYLLIKDGCRVPAVVFTTLRGRQLC APPDQPWVERIIQRLQRTSAKMKRR SS
• Endotoxin: ≤1 EUs/μg, Kinetic LAL
• Purity: ≥95%, Reducing and Non-Reducing SDS PAGE
• Stability: 12 months from date of receipt when stored at -20 to -80 centigrade as supplied.
  1 month when stored at 4 centigrade after reconstituting as directed.
  3 months when stored at -20 to -80 centigrade after reconstituting as directed.
• Storage: Storage Prior to Reconstitution: -20 centigrade
• Storage Buffer: Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA)
• Reconstitution: Sterile water at 0.1 mg/mL
• Shipping: Room temperature
• Instructions: Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80 centigrade and avoid repeat freeze thaws.

Gene Information

• Gene Name: CCL19 chemokine (C-C motif) ligand 19 [ Homo sapiens (human) ]
• Official Symbol: CCL19
• Synonyms: CCL19; chemokine (C-C motif) ligand 19; SCYA19, small inducible cytokine subfamily A (Cys Cys), member 19; C-C motif chemokine 19; beta chemokine exodus 3; CC chemokine ligand 19; CK beta 11; CKb11; EBI1 ligand chemokine; ELC; exodus 3; macrophage inflammatory protein 3 beta; MIP 3b; exodus-3; CK beta-11; MIP-3-beta; EBI1-ligand chemokine; beta chemokine exodus-3; beta-chemokine exodus-3; small-inducible cytokine A19; macrophage inflammatory protein 3-beta; epstein-Barr virus-induced molecule 1 ligand chemokine; small inducible cytokine subfamily A (Cys-Cys), member 19; MIP3B; MIP-3b; SCYA19; MGC34433
• Gene ID: 6363
• mRNA Refseq: NM_006274
• Protein Refseq: NP_006265
• MIM: 602227
• UniProt ID: Q99731

Reviews

03/29/2021

The quality of the production is stable, and the batch-to-batch and intra-batch repeatability is good.

11/10/2020

CCL19 has a complete range of specifications and is suitable for experiments of different scales.

03/09/2020

The preparation is simple and we can do it ourselves.

Q&As

What are the limitations of research on CCL19?

There are still some limitations in the current research on CCL19, such as the lack of in-depth research on its specific mechanism of action and function, and the incomplete understanding of its relationship with diseases. In addition, since CCL19 is a multifunctional protein, regulating it may also have some side effects.

Why is CCL19 related to other chemokines or proteins?

It has a complex relationship with other chemokines or proteins. For example, it binds to the CCR7 receptor, which directs the migration of immune cells. In addition, CCL19 interacts with other chemokines and cytokines to jointly regulate immune responses.

What are the treatment strategies for CCL19?

Therapeutic strategies for CCL19 include inhibition of its expression, modulation of its activity, or use of gene therapy. For example, some studies have shown that the use of small molecule inhibitors or antibodies against CCL19 can inhibit its activity and thus treat some CCL19-related diseases. In addition, related diseases can also be treated by regulating the expression level of CCL19.

How can we better understand the role of CCL19 in disease?

In order to better understand the role of CCL19 in disease, further in-depth study of its specific mechanism of action and function is needed. In addition, it is also necessary to study the changes in its expression level and activity in different diseases, as well as its relationship with the occurrence and development of diseases. At the same time, it is also necessary to explore the clinical application prospects and effects of the therapeutic strategies that regulate them. This will contribute to the development of more effective treatments to improve outcomes and quality of life for patients with CCL19-related diseases.

What is the role of CCL19 in the immune system?

CCL19 is mainly involved in the recruitment and activation of immune cells. It is able to exert immune defense by binding to receptors on the cell surface to direct immune cells to migrate to the site of inflammation or infection. In addition, CCL19 is also able to regulate the activation and differentiation of immune cells, affecting the type and intensity of immune responses.

Are there new mechanisms of action or functions in recent studies of CCL19?

Recent studies have found that CCL19 is also involved in the production and maintenance of lymphatic vessels. These processes have an important impact on the migration of immune cells and the regulation of immune responses, and also provide new ideas for the treatment of some diseases related to CCL19.